ClinicalTrials.gg
Status unknownNCT02059564Updated Feb 11, 2014

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

A Phase 1 interventional study of HM11260C and Placebo in Diabetes Mellitus, sponsored by Hanmi Pharmaceutical Company Limited. Status unknown at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-02-11.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's title name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2014), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Planned enrollment
93rd of 151
44 · median 62
Started
2013
with 17 others
Phase 1
25 of 151
none open now
Registered
93rd of 151
by date

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 93rd largest by planned enrollment, is one of 18 that started in 2013, is one of 25 in phase 1, and was the 93rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects with Type 2 Diabetes Mellitus

Read the detailed description

Primary Objective

  • effect of multiple different weekly and monthly doses of HM11260C and liraglutide (Victoza) as active control on gastric emptying

Secondary Objectives

  • evaluate the pharmacodynamic (PD) effects of multiple weekly and monthly doses of HM11260C and liraglutide after a Mixed Meal Tolerance Test
  • evaluate the islet β-cell function after a graded glucose infusion (GGI) of different doses of HM11260C and liraglutide
  • evaluate safety and tolerability of different doses of HM11260C and liraglutide
  • evaluate the pharmacokinetic (PK) effect of multiple weekly and monthly doses of HM11260C
03

Conditions studied

  • Diabetes Mellitus

Keywords

  • Diabetes Mellitus
  • Diabetes Mellitus, Type 2
  • Glucose Metabolism Disorders
  • Metabolic Diseases
  • Endocrine System Diseases
  • Exendin-4
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's planned enrollment of 44 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 to ≤ 70 years of age at the time of the Screening Visit
  • History of type 2 diabetes
  • (BMI) ≥18 to ≤45 kg/m2 at the Screening Visit
  • Use of approved methods of
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes
  • Significant acute diabetic proliferative retinopathy or severe neuropathy
  • Systolic blood pressure >160 mm Hg and/or diastolic blood pressure >100 mm Hg at screening
  • Pregnant or lactating women
  • Participation in an study within 30 days prior to randomization
  • History of any major surgery within 6 months prior to Screening
  • History of any serious adverse reaction or to any of the product components.
  • History of renal disease or significantly abnormal kidney function tests at Screening
  • History of hepatic disease or significantly abnormal liver function tests
  • History of any active infection within 30 days prior to Randomization
  • Presence of physical, laboratory, or findings at Screening that, in the opinion of the Investigator, may interfere with any aspect of study conduct or interpretation of results
  • Concurrent conditions that could interfere with safety and/or tolerability measurements per the investigator
  • Donation or loss of >500 mL of blood or blood product within 56 days of Randomization
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Cohort A

    The weekly treatment of the 6 mg HM11260C or placebo will be maintained

    Drug: HM11260C · Drug: Placebo

  • Experimental
    Cohort B

    The monthly treatment with 4 mg HM11260C or placebo will be up titrated to 16 mg

    Drug: HM11260C · Drug: Placebo

  • Experimental
    Cohort C

    The daily treatment with 0.6 mg Victoza will be up titrated to 1.2 mg

    Drug: Victoza

Interventions

  • doses of 6 mg, 16 mg

    Also known as: LAPS-Exendin-4

  • DrugPlacebo

    Normal saline solution

    Also known as: Normal saline solution

  • doses of 1.8 mg

    Also known as: Liraglutide

07

What researchers measure

Primary outcomes

  1. PK profile of acetaminophen

    Cmax, AUC at 13 weeks

    Time frame: 13 weeks

Secondary outcomes

  1. Glucose metabolism

    Fasting plasma glucose (FPG), Postprandial glucose (PPG), Insulin, C-peptide, HbA1c at 13 weeks

    Time frame: 13 weeks

  2. Safety and tolerability

    Incidence and severity of adverse events, findings on physical examination, clinical laboratory abnormalities at 18 weeks

    Time frame: 18 weeks

08

Study locations

1 of 1 sites recruiting
  • Hanmi
    California, California, United States
    Recruiting
09

References and documents

Publications

  • Hompesch M, Kang J, Han O, Trautmann ME, Sorli CH, Ogbaa I, Stewart J, Morrow L. Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study. BMJ Open Diabetes Res Care. 2021 Jun;9(1):e002208. doi: 10.1136/bmjdrc-2021-002208. PubMed 34172436 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Oct 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2014
First posted
Feb 11, 2014
Start
Dec 2013
Primary completionEst.
Oct 2014
CompletionEst.
Dec 2014
Last update
Feb 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02059564
Responsible party
Sponsor
First posted
Feb 11, 2014
Start date
Dec 2013
Primary completion
Oct 2014 (estimated)
Completion
Dec 2014 (estimated)
Last update
Feb 11, 2014

Study contacts

Hanmi Clinical
Contact
clinical4@hanmi.co.kr
Hanmi Clinical
principal investigator · California, United States

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efpeglenatide · Liraglutide

Start the discussion